LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
Help employers find you! Check out all the jobs and post your resume.
